Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Eve vs Queen RX

Eve
Graded #210

Level

vs
Queen RX
Graded #212

Level

The verdict

Too close to call — both grade 66/100 (C).

Eve and Queen RX land on the same WeighScore, so neither clears the other on our six graded dimensions. Eve sits one line higher on the board (#210 vs #212) on the underlying tiebreak, but it's a genuine coin-flip — pick on the factors and prices that matter most to you below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueQueen RX +22
54
76
Dose & formulationEve +31
88
57
Clinical oversightEve +10
79
69
Labs & monitoringQueen RX +1
52
53
FulfillmentQueen RX +8
67
75
Contract termsQueen RX +20
41
61
Eve · left barQueen RX · right bar

The numbers

MetricEveQueen RX
WeighScore66/10066/100
GradeCC
Scorecard rank#210#212
Semaglutide$195/mo (compounded)$100/mo (quarterly plan, compounded)
Tirzepatide$195/mo (compounded)Not disclosed
CoverageCoverage not published45 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
Eve

Graded #210 · C

Strengths

  • Genuinely women's-health-focused — fills a real gap among gender-neutral GLP-1 competitors
  • Both compounded and brand-name FDA-approved options (Wegovy/Ozempic/Mounjaro) on one platform — rare
  • LegitScript Certified with a verifiable ID
  • Publishes the FDA compounded-medication disclaimer
  • Oral sublingual semaglutide offered alongside injectable

Where it loses points

  • Full states-served list not disclosed publicly
  • 503A pharmacy partner not named, and 503A vs 503B status not specified
  • Named medical director / clinical leadership not disclosed
  • Corporate legal entity not disclosed
  • Governing law / arbitration venue not stated
Queen RX

Graded #212 · C

Strengths

  • $299/quarter (~$100/mo) — among the lowest GLP-1 pricing in the dataset
  • Three GLP-1 options: semaglutide, tirzepatide, and liraglutide
  • 45-state coverage

Where it loses points

  • No LegitScript or PCAB accreditation
  • No legal entity name or address disclosed
  • No named pharmacy partners
  • Not available in KS, LA, MS, NM, WV

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard